Thank you very much. And hi everyone, welcome to Cinclus Pharma's third quarter 2025 earnings call. Here with me today, I also have our CFO, Maria Engström, and our R&D director, Margit Mahlapuu. We will present the latest developments from Q3 2025 and the upcoming news after, and after this presentation, we will be happy to answer any questions you may have. And before we begin, I would like to share a quick reminder with our listeners that during today's call, we may make forward-looking statements that involve known and unknown risks, uncertainties, and other important factors beyond the company's control that could cause the company's actual results, performance, or achievements to be materially different from the expected results, performance, or achievements expressed or implied by such forward-looking statements. Please note that these forward-looking statements made during this call speak only as of today's date, and the company undertakes no obligation to update them to reflect subsequent events or circumstances other than to the extent required by law. So with that said, let's go then into the business.
And many of you listeners know about our substance, Linaprazan glurate, which is our next-generation PCAB. We have definitely designed it to deliver unique 24-hour acid control. We also have the fastest onset of action observed to date in the class overall, and this presents a significant opportunity to position the product as best in class. We have finalized our Phase 2 with very strong results, demonstrating high healing rates, especially in severe erosive GERD patients. And now we have also initiated the Phase 3 program, which is definitely a very, very big milestone for us as a company.
An important step towards approval later on. The first patient has been enrolled. You will learn more about that today.
I would say that the first Phase 3 study remains significantly and clinically de-risked. We are also strongly backed by a clear regulatory strategy and extensive preclinical and clinical validations. Overall, the program looks very de-risked, and our commercial focus remains on patients with severe erosive GERD, where you find the highest unmet medical need and where Linaprazan glurate's superior acid control can deliver the greatest benefit. And I think that's important.
And that is something we will further develop in the future as well. With this unique pharmacokinetic and pharmacodynamic profile, it provides strong differentiation compared to both PPIs currently on the market, as well as against all other PCABs both now and in the future.
Additionally, this unique profile supports a specialty commercial model, which is also important for future commercialization. It's also interesting to observe that there's an increase in global momentum for PCABs overall, in regions where they have been launched. And now, we actually see that PCABs are available in over 30 countries. They are also replacing PPIs in markets where they have been launched and integrated into treatment guidelines for erosive GERD. So it looks very promising for the class overall. And moving to the next slide, where we're examining the correlation between healing and pH level, as you can see, there is a clear linear relationship between the 24-hour gastric acid control, at approximately pH four, and the healing of erosive GERD.
The more intragastric pH stays above four, the higher the healing rates observed at four and eight weeks.
This relationship is consistent across multiple studies and thousands of patients. When you look at PPIs, first-generation PCABs like Vonoprazan, or new compounds like Tegoprazan.
As you can see, the relationship is evident everywhere, and overall, PPIs, the current standard of care, achieve approximately 60 to 70% acid control. The first generation of PCABs achieves something between 60% to 85% in acid control.
We, as a unique next-generation product, come close to 100% or 96% in our studies. So it's really a unique possibility here. So this correlation reinforces that acid control is the key biomarker for clinical healing. And it's exactly where Linaprazan glurate differentiates with our superior 24-hour control. I mean with our superior 24-hour control and the fastest onset of action.
So if you just look at the next slide, this slide is built on the previous one and illustrates how the correlation between pH above four and healing is fully aligned with the data from other studies and especially from the Vonoprazan US Phase 3 trial as shown here. From that study, Lansoprazole 30mg maintains pH around 66% of the time, resulting in approximately a 70% healing rate after eight weeks for severe patients. In comparison, in the same study, Vonoprazan 20mg achieved 85% pH above four, corresponding to approximately a 90% healing rate after eight weeks. It's spot on the line which we just mentioned. And what you can also see then, if you look into our study, where we have shown 96% pH above four, is that if you plot it into the same line here, it will translate into nearly complete healing for the most severe erosive GERD patients. This is very strong data. Reinforced acid control is the single most important determinant of healing. The superior pharmacodynamic profile of Linaprazan glurate provides a clear competitive advantage over both PPIs and other PCABs. So taking these together, this supports our Phase 3 dose selection and underpins our confidence in achieving best-in-class outcomes in the ongoing HEALING-1 study.
I also wanted to mention a little bit about the overall market, which I introduced at the beginning of the presentation. Looking into the PCABs, the global PCAB market continues to expand rapidly, driven by strong demand for fast and durable acid control. And that also shows the unmet medical need. In the US, for instance, the launch of Phathom's Vonoprazan is progressing well. The company projects approximately 107 to 175 million USD in sales this year, and they already have nearly 800,000 prescriptions filled to date. Actually, they expect profitability next year, 2026.
We also foresee and expect an NDA for Tegoprazan to be submitted this quarter by the company Sebela, which will further expand US category visibility, obviously. As I said initially, PCABs are now available in more than 25-30 markets worldwide, reflecting a broad clinical and commercial adaptation.
In Japan, the first adopter market for PCABs accounts for approximately 44% of the entire acid blocker segment. And as you know, at the peak, they were close to 1 billion USD in sales only in Japan, while in South Korea, PCABs are already approved, representing approximately 23% of all acid blocker prescriptions, with double-digit annual growth. And it is definitely continuing to displace PPIs in other markets, such as India, where we're seeing rapid uptake. More than 20 brands launched, 13 licensing deals signed, and treatment guidelines updated to recommend first-line use for P-CABs in Mexico and Latin America.
P-CABs have reached position number three in the market within just two years. Out. Pricing. Traditional PPIs. Everywhere P-CABs are launched, the future looks very promising. Combining these trends highlights a clear global shift towards P-CABs, reinforcing the strong commercial potential for Linaprazan glurate as the next-generation best-in-class therapy.
So let's go in to the events during the quarter. During the third quarter, as we have already mentioned, we received positive feedback from regulatory authorities allowing us to initiate the Phase 3 HEEALING-1 study. And we're going to evaluate erosive GERD patients across all grades, focusing on the primary endpoint, where we aim to deliver superiority for the severe erosive GERD patients in four weeks.
We have now initiated the Phase 3 trial, which will enroll approximately 500 patients in up to 100 clinical sites across seven European countries.
We have dosed the first patients, and you will soon learn more about that. That actually happened during October. And that is, of course, an important milestone for us as a company and also for the substance. We have also presented an abstract at the biggest European congress in Berlin, highlighting the positive data from optimized tablet formulation developed for the Phase 3 and also for commercialization later on.
In addition, an important step forward is the NDA. We received positive feedback from the FDA following the CMC meeting, confirming alignment on our manufacturing and quality strategy in preparation for an NDA submission.
With that said, I will now hand over to Margit to present updates on the ongoing Phase 3 HEEALING-1 study, so please go ahead. Margit.